No Data
Express News | Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference
Pieris Pharmaceuticals' Merger Partner Palvella Therapeutics Receives FDA Office Of Orphan Products Development Grant Of Up To $2.6M For Phase 3 SELVA Trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations
Palvella Therapeutics Awarded Up to $2.6 Million Grant From the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations
Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 Loss per Share (Vs US$3.63 Profit in 2Q 2023)
We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
No Data
No Data